Search by individual drug
*The Area Prescribing Committee may accept shared care guidelines that have been produced by other organisations.
| Drug | Indications | Drug class |
|---|---|---|
| 3,4-diaminopyridine | Lambert-Eaton myasthenic syndrome (LEMS) | Red |
| 5-methoxypsoralen | PUVA treatment of psoriasis | Red |
| Abacavir | HIV infection | Red |
| Abacavir/dolutegravir/lamivudine | HIV infection | Red |
| Abacavir/lamivudine | HIV infection | Red |
| Abaloparatide | Male and juvenile osteoporosis | Red |
| Abatacept | All indications | Red |
| Abiraterone | Treatment of cancer | Red |
| Acamprosate | Maintain abstinence in alcohol-dependent patients | Amber |
| Acetylcysteine sachets | Intestinal obstruction | Green Specialist Initiation |
| Acetylcysteine | Interstitial lung disease | Green Specialist Initiation |
| Acetylcysteine | Red for newly diagnosed patients with cystic fibrosis (CF) | Red |
| Acitretin | Oral retinoid for psoriasis | Red |
| Aclidinium bromide powder inhaler | Chronic obstructive pulmonary disease (COPD) | Green |
| Adalimumab | All indications | Red |
| Adefovir | Hepatitis B | Red |
| Afatinib | Treatment of cancers | Red |
| Agalsidase alfa | Fabry's disease | Red |
| Aflibercept | All indications | Red |
| Agalsidase beta | Fabry's disease | Red |
| Agomelatine | Antidepressant (amber for existing patients) | Red for new patients. Amber |
| Albumin-bound paclitaxel | Treatment of cancer | Red |
| Albutrepenonacog alfa | Haemophilia B | Red |
| Albutropin | Adult onset growth hormone deficiency | Red |
| Aldesleukin | Treatment of cancers | Red |
| Alemtuzumab | All indications | Red |
| Alglucosidase alfa | Pompe disease | Red |
| Alipogene tiparvovec | Lipoprotein lipase deficiency | Red |
| Aliskiren | Stage 4 hypertension | Green Specialist Initiation |
| Alisporivir | Hepatitis C | Red |
| Alitretinoin | Severe chronic hand eczema refractory to potent topical corticosteroids | Red |
| Alogliptin | Type 2 diabetes (T2DM) | Green |
| Alpha-1 antitrypsin | Alpha-1 antitrypsin deficiency | Red |
| Alpha mannosidase recombinant human | Alpha mannosidase deficiency | Red |
| Alteplase | Thrombolytic | Red |
| Ambrisentan | Pulmonary arterial hypertension | Red |
| Amiodarone | Arrhythmias | Green Specialist Initiation |
| Amifampridine | Lambert-Eaton myasthenic syndrome (LEMS) | Red |
| Amikacin inhalation | Cystic fibrosis (CF) | Red |
| Amikacin liposomal | Cystic fibrosis (CF) | Red |
| Amphotericin liposomal | Fungal infections | Red |
| Amisulpride | Atypical antipsychotic for schizophrenia | Green Specialist Initiation |
| Anagrelide | Essential thrombocythaemia | Red |
| Anakinra | Rheumatoid arthritis (RA) | Red |
| Anastrozole | Breast Cancer - long term therapy | Green Specialist Initiation |
| Anidulafungin | IV antifungal agent | Red |
| Anoro Ellipta 55/22® | Chronic obstructive pulmonary disease (COPD) | Green |
| Antihistamines for hay fever (OTC or prescription) | See separate grey list (DROP-List) | Grey (DROP-List) |
| Antihaemophilic factor/Von Willebrand factor complex | As per BCSH guidelines for specialised indications | Red |
| Antilymphocyte globulin | Aplastic anaemia organ transplant | Red |
| Antipseudomonas aeruginosa IgY | Cystic fibrosis (CF) | Red |
| Antithrombin III | As per BCSH guidelines for specialised indications | Red |
| Antithymocyte immunoglobulin | Aplastic anaemia organ transplant | Red |
| Anti-retrovirals | HIV infection | Red |
| Antox® | Anti-oxidant therapy for pancreatitis | Green Specialist Initiation |
| Apixaban | See DOACs | See DOACs |
| Apomorphine | Parkinson's disease | Amber |
| Apremilast | According to NICE (TA433) for the treatment of active psoriatic arthritis & (TA419) for treating moderate to severe plaque psoriasis | Red |
| Aprepitant | Nausea/vomiting with highly emetogenic chemotherapy | Red |
| Aripiprazole | Schizophrenia | Green Specialist Initiation |
| Asenapine | Treatment of bipolar disorders | Red |
| Asfotase alfa | Hypophosphatasia | Red |
| Asunaprevir with daclatasvir | Hepatitis C | Red |
| Atacicept | Systemic lupus erythematosus (SLE) | Red |
| Ataluren | Duchenne muscular dystrophy | Red |
| Atazanavir | HIV infection | Red |
| Atazanavir/cobicistat | HIV infection | Red |
| Atomoxetine | For attention deficit hyperactivity disorder (ADHD) in school-age children, adolescents and adults | Amber |
| Avanafil | Penile rehabilitation post radical prostatectomy or radiotherapy | Black |
| Avanafil | Erectile dysfunction in adult males | Green |
| Avoralstat | Hereditary angioedema | Red |
| Axitinib | Treatment of cancers | Red |
| Azacitidine | Treatment of cancers | Red |
| Azathioprine | Licensed indications - rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, auto-immune hepatitis Off-label indications - systemic vasculitis, inflammatory bowel diseases (Crohn’s disease, ulcerative colitis, microscopic colitis) | Amber |
| Azathioprine | Dermatological conditions. Off-label: bullous pemphigoid, eczema, vasculitis & Behcets syndrome | Amber |
| Azathioprine | Transplant immunosuppression | Red |
| Azithromycin | Long term treatment bronchiectasis & COPD | Green Specialist Initiation |
| Aztreonam lysine | Red for newly diagnosed cystic fibrosis (CF) Patients | Red |
| Baricitinib | Paediatric indications (where adult NICE TA available) | Red |
| Basiliximab | Renal transplant | Red |
| BCG vaccine | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care |
| Becaplermin | Treatment of diabetic ulcers | Red |
| Beclabuvir | Hepatitis C | Red |
| Bedaquiline | TB | Red |
| Begelomab | Graft versus host disease | Red |
| Belatacept | Renal transplant | Red |
| Belimumab | Systemic lupus erythematosus (SLE) | Red |
| Bendamustine | Cancer treatment | Red |
| Benralizumab | Asthma | Red |
| Benzbromarone | Unlicensed medicine - Gout | Red |
| Beractant | Respiratory distress syndrome | Red |
| Betaine | Homocystinuria | Red |
| Bevacizumab | All indications | Red |
| Bexarotene | Treatment of cancers | Red |
| Bicalutamide | Locally advanced prostate cancer at high risk of disease progression. Locally advanced non-metastatic prostate cancer when surgical castration or other medical intervention inappropriate. Ongoing monotherapy for prostate cancer in patients wishing to preserve sexual function. Maximum androgen blockade – use continuously in conjunction with LHRH analogue for three months | Amber |
| Bimagrumab | Inclusion body myositis | Red |
| Bimatoprost/timolol eye drops (Ganfort®) | Glaucoma | Green Specialist Initiation |
| Biopatch® | Prevention of catheter site infection | Red |
| Biotin | Vitamin induced hair loss. Multiple sclerosis (MS) | Red |
| Bivalirudin | Use in perctaneous coronary intervention procedures | Red |
| Blisibimod | Systemic lupus erythematosus (SLE) | Red |
| Boceprevir | Hepatitis C | Red |
| Bone morphogenic protein (dibotermin, eptotermin) | Bone fractures. See bone morphogenic protein commissioning statement | Red |
| Bone morphogenic protein (dibotermin, eptotermin) | Complex spinal surgery | Red |
| Bortezomib | All indications | Red |
| Bosentan | All indications | Red |
| Bosutinib | Cancer | Red |
| Botulinum toxin | All indications | Red |
| Brentuximab | Treatment of cancer | Red |
| Brimonidine gel | Treatment of facial erythema of rosacea in adults | Black |
| Brincidofovir | Cytomegalovirus | Red |
| Brivaracetam | As an adjunctive third line treatment option for the management of partial-onset seizures with or without secondary generalisation in adults. Brivaracetam may be considered if there is: • failure of one or more first line drugs (carbamazepine, lamotrigine or levetiracetam) AND • failure of one or more 2nd line drugs (topiramate, pregabalin, lacosamide, zonisamide or perampanel) | Green Specialist Initiation |
| Brodalumab | Paediatric indications (where adult NICE TA available) | Red |
| Bulkamid | Periurethral injection for the management of female stress incontinence | Red |
| Buserelin | Gonadorelin analogue - IVF | Red |
| Busulfan | Treatment of cancer | Red |
| C1 esterase inhibitors | Hereditary angioedema | Red |
| Cabazitaxel | Treatment of cancers | Red |
| Cabozantinib | Treatment of cancers | Red |
| Canakinumab | Cryopyrin associated periodic syndrome and juvenile arthritis - paediatric | Red |
| Cabergoline | Parkinson's disease | Green Specialist Initiation |
| Calcipotriol / betamethasone scalp gel | Psoriasis | Green |
| Canagliflozin | Type 2 diabetes (T2DM) | Green |
| Capecitabine | All indications | Red |
| Caphosol® oral rinse | For the prevention and treatment of mucositis caused by high dose chemotherapy | Red |
| Capsaicin patches 8% (Qutenza®) | Neuropathic pain | Red |
| Carglumic acid | Urea cycle disorders | Red |
| Carnitine | Carnitine deficiency | Red |
| Caspofungin | Fungal infections | Red |
| Catridecacog | Congenital factor XIIIa-subunit deficiency | Red |
| Ceralifimod | Multiple sclerosis (MS) | Red |
| Ceritinib | All indications | Red |
| Cerliponase alfa | Neuronal ceroid lipofuscinosis | Red |
| Certolizumab pegol | All indications | Red |
| Cetrorelix | IVF | Red |
| Cetuximab | Treatment of cancers | Red |
| Chenodeoxycholic acid | Cerebrotendinous xanthomatosis and primary biliary cirrhosis | Red |
| Chloral Hydrate | Insomnia (Short term use) | Red |
| Chlorambucil | Treatment of cancers | Red |
| Chlordiazepoxide | Acute alcohol withdrawal | Red |
| Cholic acid | Inborn errors in primary bile acid synthesis | Red |
| Chondroitin | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Chondriotin sulphate | Bladder instillation for Patients with damaged or glycosaminoglycan deficient bladder epithelium | Red |
| Chorionic gonadotrophin | Gonadorelin analogue - IVF | Red |
| Ciclosporin | Inflammatory bowel disease | Amber - SCG not available for this indication. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. |
| Ciclosporin | Licensed indications: rheumatoid arthritis, psoriasis. Off-label indication: psoriatric arthritis | Amber |
| Ciclosporin | Dermatological conditions. Licensed: atopic dermatitis. Off-label: bullous pemphigoid, pyoderma gangrenosum, hidradenitis suppurativa, pemphigus & lupus | Amber |
| Ciclosporin | Bone marrow transplant | Amber - SCG not available for this indication. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. |
| Ciclosporin | Post-transplant | Amber |
| Ciclosporin eye drops 1mg/ml (Ikervis®) | Persistent dry eye (NICE TA369) | Green Specialist Initiation (Indications other than NICE TA369 are Red) |
| Cidofovir | Cytomegalovirus | Red |
| Cinacalcet | Hypercalcaemia of primary hyperparathyroidism or parathyroid carcinoma | Amber |
| Cinacalcet | Secondary hyper-parathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | Amber |
| Cinacalcet | Hyperparathyrodism in dialysis patients | Red |
| Ciprofloxacin inhalation | Cystic fibrosis (CF) | Red |
| Ciprofloxacin liposomal (inhaled) | Cystic fibrosis (CF) | Red |
| Cladribine | Multiple sclerosis (MS) and pulmonary Langerhans histiocytosis | Red |
| Clinical trials material | All trials | Red |
| Clofarabine | Treatment of cancers | Red |
| Clomifene | IVF treatment | Red |
| Clopidogrel | Green | |
| Clozapine | Atypical Antipsychotic - Schizophrenia | Red |
| Cobicistat | HIV infection | Red |
| Cobitolimod | Paediatric indications (where adult NICE TA available) | Red |
| Co-careldopa intestinal gel | Severe Parkinson's disease | Red |
| Co-Enzyme Q10 | Enzyme deficiency in children | Red |
| Colief® drops | See separate grey list (DROP-List) | Grey (DROP-List) |
| Colesevelam | Hyperlipidaemia | Green |
| Colestilan | Renal dialysis - adults | Red |
| Colistimethate sodium | Red for newly diagnosed cystic fibrosis (CF) patients | Red |
| Colistimethate sodium - (Colomycin®) | Cystic fibrosis (CF) management | Amber - SCG not available for this indication. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. |
| Colistimethate sodium - (Promixin®) | Cystic fibrosis (CF) management | Amber |
| Colistimethate sodium - (Colomycin®) | Pseudomonas infection in the lungs | Amber |
| Conestat alfa | Hereditary angioedema | Red |
| Co-proxamol | All indications NHSE items that should not be routinely prescribed in Primary Care | Black |
| Cough and cold remedies | See separate grey list (DROP-List) | Grey (DROP-List) |
| Crizotinib | Treatment of cancers | Red |
| Cyclophosphamide | All Indications | Red |
| Cyproterone | Prostate cancer | Amber |
| Cyproterone (off-label indications) | Off-label indications | Red |
| Cytotoxic injectable drugs | All indications | Red |
| Dabigatran | See DOACs | See DOACs |
| Dabrafenib | Treatment of cancer | Red |
| Daclatasvir | Hepatitis C | Red |
| Daclizumab | Multiple sclerosis (MS) | Red |
| Dalteparin | Urgent bridging of patients on warfarin (for VTE or heart valve), with significantly sub-therapeutic INR, in accordance with Trust dosing guidance (taking account of patient weight and renal function) | Green Specialist Initiation |
| Dalteparin | Pre-procedural bridging therapy for patients usually on warfarin (as directed by surgeon/clinical haematologist). Extended post-operative thromboprophylaxis. High risk patients with plaster cast (~6 weeks whilst immobile) – off-label. Treatment of acute VTE & maintenance during pregnancy. Antenatal thromboprophylaxis in women at high risk of VTE in pregnancy. Postpartum thromboprophylaxis in high risk women (7 days or 6 weeks) | Red |
| Dapagliflozin | Type 2 diabetes (T2DM) | Green |
| Dapoxetine | Premature ejaculation | Black |
| Dapsone | Licensed indication- Dermatitis herpetiformis, and off-label indications - dermatoses (leucocytoclastic vasculitis, Sweet's syndrome, pyoderma gangrenosum) | Amber |
| Daratumunab | For the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy | Red |
| Darbepoetin alfa | All indications | Red |
| Darunavir | HIV treatment | Red |
| Darunavir/cobicistat | HIV treatment | Red |
| Dasabuvir | Hepatitis C | Red |
| Dasatinib | Treatment of cancers | Red |
| Daunorubicin | Treatment of cancers | Red |
| Decitabine | Treatment of cancers | Red |
| Deferasirox | Iron chelation in thalassaemia and sickle cell | Red |
| Deferiprone | Iron chelation in thalassaemia and sickle cell | Red |
| Defibrotide | Hepatic veno-occlusive disease | Red |
| Degarelix | Prostate cancer | Red |
| Delamanid | Extensively drug-resistant TB and multi drug-resistant TB | Red |
| Denosumab | Prevention of osteoporosis | SWYAPC (please note this shared care guideline has not been adopted by Bradford CCGs) |
| Denosumab | Prevention of skeletal events from breast cancer | Red |
| Dental products on FP10 | Black with the exception of those patients on specialist advice following treatment for head and neck cancers (GSI) See NHSE Guidance on the conditions for which over the counter items should not routinely be prescribed in primary care. |
|
| Desferrioxamine | Iron chelation in thalassaemia and sickle cell | Red |
| Desferrioxamine | Treatment of iron overload | Amber |
| Dexamethasone intravitreal implant | Macular oedema | Red |
| Dexamfetamine | For attention deficit hyperactivity disorder (ADHD) in school-age children, adolescents and adults | Amber |
| Dexmedetomide | Maintenance of sedation during intensive care | Red |
| Dexrazoxane | Anthracycline extravasation and cardiotoxicity | Red |
| Dibotermin alfa | Bone fractures | Red - see bone morphogenic protein commissioning statement |
| Dibotermin alfa | Complex spinal surgery | Red |
| Didanosine | HIV infection | Red |
| Dihydrotestosterone (Androstanolone®) | Unlicensed - recommendation from Leeds paediatric surgeons | Red |
| Dimethyl fumarate | Multiple sclerosis (MS) / Psoriasis | Red |
| Dinoprostone (Propess®) | Cervical ripening/induction of labour | Red |
| Disodium pamidronate (IV) | Bisphosphonate - all licensed indications | Red |
| Disulfiram | Management of patients with drinking problems | Amber |
| DOACs | Red for prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery. Red for acute coronary syndrome (ACS). Full courses supplied through Acute Trust. GSI for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults, subject to local policy. Green for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation, with one or more risk factors, subject to local policy. Check licensed indications and doses of individual drugs | Red for prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery. Red for acute coronary syndrome (ACS). Full courses supplied through Acute Trust. GSI for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults, subject to local policy. Green for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation, with one or more risk factors, subject to local policy. Check licensed indications and doses of individual drugs |
| Docetaxel | Advanced/metastatic breast cancer, prostate cancer | Red |
| Dolutegravir | HIV Infection | Red |
| Donepezil | Mild to moderate dementia in Alzheimer's disease | Green Specialist Initiation |
| Dornase alfa | Red for newly diagnosed CF Patients | Red |
| Dornase alfa | Cystic fibrosis (CF) management | Amber |
| Dornase alfa | Primary ciliary dyskinesia | Red |
| Dosulepin | All indications | Black for new patients for all indications NHSE items that should not be routinely prescribed in Primary Care |
| Doxazosin MR | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Drisapersen | Duchenne muscular dystrophy | Red |
| Dronedarone | Cardiac arrhythmia | Green Specialist Initiation |
| Droperidol injection | Post operative nausea and vomiting | Red |
| Duloxetine | Green | |
| Dupilumab | Asthma | Red |
| Ecallantide | Hereditary angioedema | Red |
| Eculizumab | All indications | Red |
| Edoxaban | See DOACs | See DOACs |
| Edratide | Systemic lupus erythematosus (SLE) | Red |
| Efavirenz | HIV infection | Red |
| Eflornithine cream (Vaniqa®) | See separate grey list (DROP-List) | Grey (DROP-List) |
| Efraloctocog alfa/efmoroctocog alfa/factor VIII FC fusion protein | Haemophilia A | Red |
| Efmoroctocog alfa | Haemophilia | Red |
| Elbasvir | Hepatitis C | Red |
| Eliglustat | Gaucher's disease | Red |
| Elosulfase alfa | Lysosomal storage disorders | Red |
| Eltrombopag | Idiopathic thrombocytopenic purpura | Red |
| Elvitegravir | HIV infection | Red |
| Emricasan | Non-alcoholic steatohepatitis fibrosis | Red |
| Emtricitabine | HIV infection | Red |
| Emtricitabine/elvitegravir/cobicistat/tenofovir alafenamide fumarate | HIV infection | Red |
| Emtricitabine/rilpivirine/tenofovir alafenamide fumarate | HIV infection | Red |
| Emtricitabine/tenofovir alafenamide fumarate | HIV Infection | Red |
| Enfuvirtide | HIV Infection | Red |
| Enstilar® (calcipotriol and betamethasone) | Green if failed on individual components | |
| Entecavir | Chronic Hepatitis B infection | Red |
| Enzalutamide | Treatment of cancers | Red |
| Epoetin | Dialysis-induced anaemia - red. All other indications- amber | Dialysis-induced anaemia - red. All other indications amber - SCG not available Please see amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. |
| Epoprostenol | Off-label indications and pulmonary arterial hypertension | Red |
| Epratuzumab | Systemic lupus erythematosus (SLE) | Red |
| Eprodisate | Amyloidosis | Red |
| Eptotermin alfa | Bone fractures | Red - see bone morphogenic protein commissioning statement |
| Eptotermin alfa | Complex spinal surgery | Red |
| Eribulin | Treatment of cancers | Red |
| Erlotinib | Treatment of cancers | Red |
| Estramustine | Treatment of cancers | Red |
| Etanercept | All indications | Red |
| Eteplirsen | Duchenne muscular dystrophy | Red |
| Ethambutol | Treatment of TB | Red |
| Etoposide | Treatment of cancers | Red |
| Etravirine | HIV treatment | Red |
| Etrolizumab | Paediatric indications (where adult NICE TA available) | Red |
| Everolimus (Afinitor®) | Treatment of cancers | Red |
| Everolimus (Certican®) | Preventing transplant rejection | Red |
| Everolimus (Votubia®) | Tubular sclerosis | Red |
| Evicel® | Tissue adhesive - for use in patients undergoing pelvic surgery or laparoscopic partial nephrectomies | Red |
| Evolocumab | Homozygous familial hypercholesterolaemia | Red |
| Exemestane | Breast Cancer | Green Specialist Initiation |
| Exenatide | Type 2 diabetes (T2DM) | Green |
| Exenatide weekly | Type 2 diabetes (T2DM) | Green |
| Ex-vivo expanded autologous human corneal epithelial cells containing stem cells | Limbal stem cell deficiency | Red |
| Factor IX | As per BCSH guidelines for specialised indications | Red |
| Factor VII | As per BCSH guidelines for specialised indications | Red |
| Factor VIIa (Recombinant) (NovoSeven®) | Bleeding episodes in surgery in specific patients | Red |
| Factor VIIa | As per BCSH guidelines for specialised indications | Red |
| Factor VIII | As per BCSH guidelines for specialised indications | Red |
| Factor VIII inhibitor bypassing factor | As per BCSH guidelines for specialised indications | Red |
| Factor XIII | As per BCSH guidelines for specialised indications | Red |
| Fampridine | Multiple sclerosis (MS) | Red |
| Febuxostat | In line with NICE for patients intolerant of allorpurinol | Green |
| Fentanyl nasal spray (Instany®l) | Pain relief - use should be restricted to palliative care consultants | Green Specialist Initiation |
| Fentanyl IR | For non palliative care indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Ferric carboxymaltose (Ferinject®) | Iron-deficiency anaemia | Red |
| Ferric carboxymaltose (Ferinject®) | Heart failure patients with or without decreased haemoglobin levels | Red |
| Fesoterodine | Overactive bladder syndrome | Green |
| Fiasp® (insulin aspart) | Treatment of diabetes in adult patients with Type 1 diabetes who are likely to benefit directly from a more rapid onset of action, including: 1.Pregnancy 2.Use of insulin pump 3.Young adults unable to manage with Novorapid because of poor post-prandial glucose control, despite adequate therapeutic trial | Green Specialist Initiation |
| Fibrinogen | As per BCSH guidelines for specialised indications | Red |
| Fibroblast growth factor 1 gene therapy | Somatostatin analogue | Red |
| Fidaxomicin | Treatment of Clostridium difficile infection only when it prevents admission to hospital or severe illness | Green Specialist Initiation |
| Filgotinib | Paediatric indications (where adult NICE TA available) | Red |
| Filgrastim | Neutropenia and Barth syndrome | Red |
| Filibuvir | Hepatitis C | Red |
| Fingolimod | Management of multiple sclerosis | Red |
| Fitusiran | Haemophilia A And B | Red |
| Flecainide | Green Specialist Initiation | |
| Fludarabine | Treatment of cancers | Red |
| Fluocinolone acetonide intravitreal implant (IIuvien®) | Treatment of chronic diabetic macular oedema | Red |
| Fluorouracil / salicylic acid (Actikerall®) | Management of actinic keratosis | Green |
| Flupentixol depot injection | Depot antipsychotic for schizophrenia | Green Specialist Initiation |
| Fluphenazine depot injection | Depot antipsychotic for schizophrenia (to be discontinued at the end of 2018 - no new patients should be started on this if treatment is expected to continue beyond 2018) | Green Specialist Initiation |
| Flutamide | Advanced prostate cancer patients for: Long term palliative therapy when LHRH analogues or orchidectomy is contraindicated, not tolerated or oral therapy preferred. Hot flushes with LHRH analogue therapy or after orchidectomy | Amber |
| Fluticasone furoate nasal spray | Green | |
| Follitropin alfa/beta | IVF - Gonadotrophin | Red |
| Fondaparinux | Parenteral anticoagulant | Red |
| Forigerimod acetate | Systemic lupus erythematosus (SLE) | Red |
| Fosamprenavir | HIV Infection | Red |
| Fosaprepitant injection | Chemotherapy induced nausea and vomiting | Red |
| Foscarnet | Cytomegalovirus | Red |
| Fosfomycin IV | 2nd line antibiotic for patients with carbapenemase resistant infections or with confirmed anaphylactoid reaction to penicillins presenting with suspected meningitis | Red |
| Fosfomycin | Urinary tract infections (UTIs) (sensitivities reported by Microbiology) | Green Specialist Initiation |
| Fostemsavir | HIV infection | Red |
| Fulvestrant | Breast cancer | Red |
| Fumaric acid esters (Fumaderm®) | Psoriasis. Fumaderm was unlicensed. Licensed formulation is in development | Red |
| Galantamine | Mild to moderate dementia in Alzheimer's disease | Green Specialist Initiation |
| Galsulfase | Mucopolysaccharidosis | Red |
| Ganetespib | Treatment of cancers | Red |
| Ganciclovir | Maintenance of cytomegalovirus (CMV) retinitis in patients with AIDS. CMV disease in immunocompromised patients & patients with AIDS. Use in liver transplant patients | Red |
| Gefitinib | Oral treatment for cancer | Red |
| Gender dysphoria or reassignment drugs | Guidance available from Leeds Health Pathways (search 'gender') | See information from Leeds |
| Gevokizumab | Uveitis | Red |
| Glatiramer | Multiple sclerosis (MS) | Red |
| Glecaprevir | Hepatitis C | Red |
| Glucosamine | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Glucarpidase | Methotrexate-induced renal dysfunction | Red |
| Glycerol phenylbutyrate | Urea cycle disorders | Red |
| Glycopegylated factor IX | Haemophilia A | Red |
| Glycopyrronium (oral) | Hypersalivation | Amber Glycopyrronium SCG LTHT* |
| Glycopyrronium (topical) | Hyperhidrosis | Red |
| GnRH analogues (Leuprorelin or Triptorelin) | Endometriosis or uterine fibroids | Amber |
| GnRH analogues (Goserelin, Leuproelin, Triptorelin) | Management of prostate cancer | Amber |
| Golimumab | All indications | Red |
| Gonadorelin | IVF - hypothalmic hormone | Red |
| Goserelin | Management of prostate cancer | Amber - see GnRH analogues |
| Goserelin | IVF - gonadorelin analogue | Red |
| Goserelin | Endometriosis | Amber - SCG not available for this indication. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. |
| Granulocyte-macrophage colony-stimulating factor | Antibody-positive pulmonary alveolar proteinosis | Red |
| Grazoprevir | Hepatitis C | Red |
| Grazax® | Seasonal allergic hayfever | Red |
| Guanfacine | Attention deficit hyperactivity disorder (ADHD) in school age children, adolescents and adults | Amber |
| Haloperidol depot injection | Depot antipsychotic for schizophrenia | Green Specialist Initiation |
| Haemorrhoid preparations available over-the-counter | See separate grey list (DROP-List) | Grey (DROP-List) |
| Herbal | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Hepatitis B vaccine | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care |
| HIV-fusion inhibitors | HIV infection | Red |
| HIV-integrase inhibitors | HIV infection | Red |
| HIV vaccine | HIV infection prophylaxis | Red |
| Homeopathic medicines | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Human (haem) arginate | Hepatic porphyria | Red |
| Human menopausal gonadotrophins | IVF - Gonadotrophin | Red |
| Human heterologous liver cells | Urea cycle disorders | Red |
| Human parathyroid hormone-related protein analogue | Male and juvenile osteoporosis hypoparathyroidism | Red |
| Hyaluronic acid derivatives (injectables) | Osteoarthritis and other joint conditions | Black |
| Hydrocortisone MR | Replacement in adrenocortical insufficiency | Black |
| Hydroxycarbamide | Treatment of solid tumours | Red |
| Hydroxycarbamide | Haematological conditions | Amber |
| Hydroxycarbamide | Psoriasis (off-label) | Amber |
| Hydroxychloroquine | Rheumatoid arthritis, systemic and discoid lupus erythematosus (and related connective tissue diseases – off-label) | Amber |
| Hydroxyprogesterone Caproate (Proluton Depot®) | Prevention of recurrent miscarriages | Red |
| Ibalizumab | HIV infection | Red |
| Ibandronic acid tablets 50mg | Post-menopausal women with breast cancer | Pending Green Specialist Initiation |
| Ibandronic acid injection | Bisphosphonate - all licensed indications | Red |
| Ibrutinib | Treatment of cancers | Red |
| Icatibant | Hereditary angioedema | Red |
| Idarubicin | Treatment of cancers | Red |
| Idebenone | Duchenne muscular dystrophy | Red |
| Idelalisib | Treatment of cancers | Red |
| Idursulfase | Mucopolysaccharidosis | Red |
| Iloprost | Pulmonary arterial hypertension | Red |
| Imatinib mesilate | All indications | Red |
| Imiglucerase | Enzyme replacement - Gaucher's disease | Red |
| Imiquimod | Anogenital warts | Green Specialist Initiation |
| Imiquimod | Basal cell carcinoma | Red |
| Immunoglobulin - Intravenous (IVIg) | All indications | Red |
| Indinavir | HIV Infection | Red |
| Indocyanine dye | Ophthalmology | Red |
| Infliximab | Crohn’s disease. Rheumatoid arthritis (RA) | Red |
| Influenza intra-nasal vaccine | Green | |
| Ingenol mebotate | Management of actinic keratosis | Green |
| Insulin degludec | Diabetes mellitus (DM) | Green Specialist Initiation |
| Insulin glargine (Abasaglar®) | Diabetes mellitus (DM) | Green |
| Insulin glargine (Toujeo®) | Diabetes mellitus (DM) | Green |
| Insulin - Humulin R® - U500 | 500 unit/mL insulin for use in severely insulin resistant patients | Red |
| Interferon alfa | All licensed indications | Red |
| Interferon beta | Multiple sclerosis | Red |
| Ipilimumab | Treatment of cancers | Red |
| Irinotecan | Metastatic colorectal cancer used with 5-FU and folinic acid | Red |
| Iron sucrose (Venofer®) | Iron deficiency anaemia requiring intravenous therapy | Red |
| Isavuconazole | Fungal infection (licensed indications) | Red |
| Isoniazid | Treatment of TB | Red |
| Isotretinoin | Oral retinoid - acne | Red |
| Ivabradine | Angina in sinus rhythm | Green Specialist Initiation |
| Ivacaftor | Red for newly diagnosed cystic fibrosis (CF) patients | Red |
| Ivermectin Cream | Rosacea | Green |
| IVF Treatment | All drugs | Red |
| Ixazomib | For the treatment of adult patients with multiple myeloma who have received at least one prior therapy. | Red |
| Japanese encephalitis | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care |
| Ketamine | All indications | Red |
| Lacosamide | Resistant partial seizures | Green Specialist Initiation |
| Lamivudine | Hepatitis B treatment | Red |
| Lamivudine | HIV infection | Red |
| Lamivudine/abacavir/dolutegravir | HIV infection | Red |
| Lamivudine/zidovudine | HIV infection | Red |
| Lamivudine/zidovudine/abacavir | HIV infection | Red |
| Lanreotide | Neuroendocrine tumours, acromegaly | Amber - SCG not available for this indication. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. |
| Lanreotide | Red for NHS England indications | Red |
| Lanthanum | Control of hyperphosphataemia in patients with chronic renal failure | Amber |
| Lanthanum | Adult renal dialysis | Red |
| Lapatinib | Breast cancer | Red |
| Laquinimod | Multiple sclerosis (MS) | Red |
| Laronidase | Mucopolysaccharidosis | Red |
| Lebrikizumab | Asthma | Red |
| Ledipasvir/sofosbuvir | Hepatitis C | Red |
| Leflunomide | Rheumatoid arthritis and psoriatic arthritis | Amber |
| Lenalidomide | All indications | Red |
| Lenograstim | Recombinant human granulocyte - colony stimulating factor - neutropenia | Red |
| Letermovir | Cytomegalovirus | Red |
| Letrozole | Advanced breast cancer - long term therapy | Green Specialist Initiation |
| Leuprorelin | Endometriosis or uterine fibroids | Amber - see GnRH analogues |
| Leuprorelin | Management of prostate cancer | Amber - see GnRH analogues |
| Levetiracetam | Epilepsy | Green Specialist Initiation |
| Levofloxacin (inhaled) | Cystic fibrosis (CF) | Red |
| Lidocaine plasters | Post-herpetic neuralgia | Green Specialist Initiation |
| Lidocaine plasters | For all unlicensed use | Black NHSE items that should not be routinely prescribed in Primary Care |
| Linezolid | Antibiotic - Microbiologist initiation only | Red |
| Liothyronine and liothyronine with levothyroxine | Hypothyroidism | Black - not to be initiated in Primary Care for new patients NHSE items that should not be routinely prescribed in Primary Care |
| Lipegfilgrastim | Neutropenia | Red |
| Liraglutide | Management of obesity | Black |
| Liraglutide | Type 2 diabetes (T2DM) | Green |
| Lisdexamfetamine | For attention deficit hyperactivity disorder (ADHD) in school-age children, adolescents and adults | Amber |
| Lithium | Treatment and prophylaxis of mania, bipolar disorder and recurrent depression | Amber To refer patients back into the service who have been discharged - please see the link to the SWYPFT Service directory |
| Lithium carbonate | Motor neurone disease (MND) | Red |
| Lixisenatide | Type 2 diabetes (T2DM) | Green |
| Lixivaptan | Hyponatraemia; other endocrine uses | Red |
| Lomustine | Treatment of cancers | Red |
| Lomitapide | Homozygous familial hypercholesterolemia | Red |
| Lonafarnib | Treatment of cancers | Red |
| Lopinavir/ritonavir | HIV infection | Red |
| Loteprednol | Peri-operative use | Red |
| Loteprednol | Glaucoma | Green Specialist Initiation |
| Low Molecular Weight Heparin (LMWH) - this includes: dalteparin, enoxaparin and tinzaparin | Treatment of adult patients with venous thromboembolism (VTE) presenting clinically as deep vein thrombosis (DVT), pulmonary embolism (PE) or both. LMWH under this guideline may be used in: - •Patients unable to take warfarin and in whom a direct oral anticoagulant (DOAC) is not appropriate or contraindicated. •Patients in whom it has not been possible to stabilise on oral anticoagulant therapy and in whom a DOAC is not appropriate or contraindicated (for example: a patient with a replacement metal mitral heart valve and a sub-therapeutic INR and ‘bridging’ therapy is required). •IV drug users (where warfarin is generally considered inappropriate) and in whom a DOAC is not appropriate or contraindicated. Extended treatment & prophylaxis of VTE in adult patients with solid tumours. | Amber |
| Lubiprostone | Treatment of chronic idiopathic constipation | Green Specialist Initiation |
| Lumacaftor/ivacaftor | Cystic fibrosis (CF) | Red |
| Lurasidone | Schizophrenia (adults) | Green Specialist Initiation |
| Lutein and antioxidants | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Macimorelin | Growth failure | Red |
| Macitentan | Pulmonary arterial hypertension | Red |
| Mannitol dry powder inhaler | Treatment of cystic fibrosis in adults | Red |
| Maraviroc | HIV infection | Red |
| Masitinib | Pancreatic cancer. Gastrointestinal stoma tumour (GIST) | Red |
| Mavrilimumab | Paediatric indications (where adult NICE TA available) | Red |
| Mecasermin | Growth failure | Red |
| Melatonin MR (Circadin®) | Treatment of sleep disorders in children and young people under 18 years | Amber. Leaflet for patients Crushing Circadin tablets leaflet |
| Melatonin MR (Circadin®) | Cerebral palsy - these patients will require longer term treatment – there are no drug monitoring/blood monitoring requirements | Green Specialist Initiation |
| Melphalan | Treatment of cancers | Red |
| Memantine | Moderately severe to severe Alzheimers disease. | Green Specialist Initiation |
| Meningitis ACWY vaccine | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care |
| Mepolizumab | Asthma | Red |
| Mercaptamine (cysteamine) | Nephropathic cystinosis | Red |
| Mercaptopurine | Gastroenterology | Amber |
| Mercaptopurine | Treatment of cancers | Red |
| Mesalazine MR (Mezavant®) | For the induction of clinical and endoscopic remission in patients with mild to moderate, active ulcerative colitis. For maintenance of remission | Green |
| Mesenchymal stem cells | All indications | Red |
| Methotrexate (Oral, IM & SC) | Cancer indications | Red |
| Methotrexate (IM and SC) | Non-cancer indications | Red |
| Methotrexate (oral) | Licensed indications – Rheumatoid arthritis, Psoriatic arthritis Off-label indication - Other inflammatory arthritides, connective tissue disease (not for cancer or dermatological conditions) | Amber |
| Methotrexate (oral) | Licensed indication: severe uncontrolled psoriasis. Off-label conditions: e.g pemphigoid, pemphigus, sarcoidosis, scleroderma, dermatomyositis, eczema. See shared care guideline for further indications | Amber |
| Methylnaltrexone subcutaneous injection | Severe opioid induced constipation | Black |
| Methylphenidate | For ADHD in school-age children, adolescents and adults | Amber |
| Metyrapone | Management of patients with Cushing’s Syndrome | Red for new patients Green Specialist Initiation for existing patients |
| Metreleptin | Dyslipidaemia | Red |
| Mexiletine | Treatment of life-threatening ventricular arrhythmias | Red |
| Micafungin | Fungal infections | Red |
| Miconazole buccal (Loramyc®) | Oropharyngeal candidiasis | Green Specialist Initiation |
| Midazolam oromucosal solution (Buccolam®) | Convulsive seizures | Green Specialist Initiation |
| Midodrine | Management of hypotension | Red (will be re-classified once Shared Care Guideline is approved) |
| Migalastat | Fabry's disease | Red |
| Miglustat | Gaucher's disease/Niemann-Pick disease | Red |
| Minocycline for acne | See separate grey list (DROP-List) | Grey (DROP-List) |
| Mirabegron | Overactive bladder syndrome | Green |
| Mitotane | Treatment of cancers | Red |
| Modafinil | Treatment of adults with excessive sleepiness associated with chronic pathological conditions, including narcolepsy. Multiple sclerosis (MS) and Parkinson's disease are to be included as they are chronic pathological conditions | Amber |
| Momelotinib | Treatment of cancers | Red |
| Mycophenolate | Off-label indications –systemic lupus erythematosus (SLE), particularly lupus nephritis, other connective tissue diseases and systemic vasculitis. Treatment of myasthenia gravis in patients intolerant or non-responding to azathioprine | Amber |
| Mycophenolate | Cytotoxic immunosuppressant - prophylaxis of acute transplant rejection | Amber |
| Mycophenolate | Indications not classified as amber | Red |
| Mysimba (Naltrexone -bupropion) | For the treatment of overweight and obesity | Black |
| Nabilone | Antiemetic; Multiple sclerosis treatment | Red |
| Nafarelin | IVF - gonadorelin analogue | Red |
| Nalmefene (only for patients under the care of alcohol services including shared care) | Alcohol dependence | Red |
| Naloxegol | For opioid-induced constipation according to NICE TA345 | Green Specialist Initiation |
| Naltrexone | Maintain abstinence in alcohol-dependent patients | Amber |
| Nasal sprays available over-the-counter for symptomatic relief of hay fever and congestion | See separate grey list (DROP-List) | Grey (DROP-List) |
| Natalizumab | Multiple sclerosis (MS) | Red |
| Nelarabine | Treatment of cancers | Red |
| Nephro-vite® | Vitamin supplementation in renal impairment | Green Specialist Initiation |
| Netupitant and palonosetron | Anti-emetic for use with cancer chemotherapy | Red |
| Nevirapine | HIV infection | Red |
| Nilotinib | Treatment of cancers | Red |
| Nintedanib | Treatment of cancers; idiopathic pulmonary fibrosis | Red |
| Nitazoxanide | Unlicensed in UK - for treatment of Cryptosporidiosis and Giardiasis | Red |
| Nitazoxanide | Hepatitis C | Red |
| Nitisinone | Alkaptonuria; tyrosinaemia | Red |
| Nitric oxide | Pulmonary arterial hypertension | Red |
| Nivolumab | Treatment of cancers | Red |
| NOACs | See DOACs | See DOACs |
| Nonacog alpha | Haemophilia B | Red |
| Nonacog beta pegol | Haemophilia B | Red |
| Non-nucleoside reverse transcriptase inhibitors | HIV infection | Red |
| Nucleoside reverse transcriptase inhibitors (nucleoside analogues) | HIV infection | Red |
| Obeticholic acid | Primary biliary cirrhosis | Red |
| Obinutuzumab | Treatment of cancers | Red |
| Ocrelizumab | Multiple sclerosis (MS) | Red |
| Ocriplasmin | Retinal disorders | Red |
| Octocog alfa | Haemophilia A | Red |
| Octreolin | Acromegaly | Red |
| Octreotide | For palliative care indications | Green Specialist Initiation |
| Octreotide | Amber for licensed CCG funded indications (symptoms associated with carcinoid tumours with features of carcinoid syndrome, VIPomas, glucagonomas, acromegaly, prevention of complications after pancreatic surgery). Red for NHS England indications | Amber - SCG not available. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. Red for NHS England indications |
| Octreotide (off-label indications) | Off-label indications | Red |
| Ofatumumab | Cancer and pemphigus vulgaris | Red |
| Olanzapine (IM injection) | Atypical antipsychotic - schizophrenia and bipolar disorders | Red |
| Olanzapine (oral) | Atypical antipsychotic - schizophrenia and bipolar disorders | Green Specialist Initiation |
| Olaparib | Treatment of cancers | Red |
| Olesoxime | Spinal muscular atrophy | Red |
| Omalizumab | Prophylaxis of allergic asthma | Red |
| Ombitasvir/paritaprevir/ritonavir | Hepatitis C | Red |
| Omega 3 and other fish oils | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Oralide® gel and mouthwash | Oral hygeine | Red |
| Osilodrostat | Cushing's disease | Red |
| Osimertinib | Treatment of cancers | Red |
| Oxaliplatin | Metastatic colorectal cancer used with 5-FU and folinic acid | Red |
| Oxcarbazepine | Epilepsy | Green Specialist Initiation |
| Oxycodone and naloxone MR | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Ozanimod | Multiple sclerosis (MS) | Red |
| Pacritinib | Myelofibrosis | Red |
| Paliperidone | Antipsychotic | Red |
| Palivizumab | Prophylaxis of respiratory syncytial virus (RSV) for children | Red |
| Pancreatin preparations | Pancreatic insufficiency | Green Specialist Initiation |
| Panitumumab | Treatment of cancers | Red |
| Panobinostat | Treatment of cancers | Red |
| Para-aminosalicylic acid | TB | Red |
| Paracetamol and tramadol | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Parathyroid hormone | Specialist endocrinology conditions | Red |
| Paromomycin | Treatment of cryptosporidium in immunocompromised patients | Red |
| Paritaprevir | Hepatitis C | Red |
| Pasireotide | Acromegaly; Cushing's disease | Red |
| Pazopanib | Treatment of cancers | Red |
| Pegaspargase | Treatment of cancers | Red |
| Pegylated liposomal doxorubicin | Treatment of cancers | Red |
| Peg-filgrastim (Neulasta®) | Reduction in neutropenia with cytotoxic chemotherapy | Red |
| Peg-interferon alfa | Treatment of hepatitis B and C, patients not tolerating conventional terferons | Red |
| Peginterferon beta-1a | Multiple sclerosis (MS) | Red |
| Peginterferon lambda-1A | Hepatitis C | Red |
| Pegvisomant | Acromegaly | Red |
| Pembrolizumab | Melanoma | Red |
| Pemetrexed | Treatment of cancers | Red |
| Pentosan Polysulphate (Elmiron®) | Interstitial Cystitis (Unlicensed) | Red |
| Penicillamine | Rheumatoid arthritis (RA) | Amber |
| Peptide receptor radionucelotide therapy | Treatment of cancers | |
| Perampanel | Adjunctive treatment of partial onset seizures | Green Specialist Initiation |
| Pergolide | Parkinson's disease | Green Specialist Initiation |
| Perindopril arginine | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Pertuzumab | Treatment of cancers | Red |
| Phenelzine | Treatment resistant depression | Amber |
| Phenylbutazone | NSAID - ankylosing spondylitis | Red |
| Phenylephrine/tropicamide ophthalmic insert (Mydriasert®) | Surgical mydriasis | Red |
| Phytomenadione capsules | Not licensed in UK | Green Specialist Initiation |
| Pipotiazine depot injection | Depot antipsychotic for schizophrenia | Green Specialist Initiation |
| Pirfenidone | Antifibrotic for idiopathic pulmonary fibrosis | Red |
| Pivmecillinam | Green | |
| Pixantrone | Treatment of cancers | Red |
| Plerixafor | Stem cell mobilisation | Red |
| Pomalidomide | Treatment of cancers | Red |
| Ponatinib | Treatment of cancers | Red |
| Ponesimod | Multiple sclerosis (MS) | Red |
| Poractant alfa | Respiratory distress syndrome | Red |
| Posaconazole | All indications | Red |
| Potassium iodide | For treatment of erythema nodosum | Red |
| Pramipexole | Restless legs syndrome | Green |
| Pramipexole | Parkinson's disease | Green Specialist Initiation |
| Pramipexole MR | Parkinson's disease | Green Specialist Initiation |
| Prasugrel | Cobination with aspirin for the prevention of atherothrombotic events in patients with acute coronory syndrome undergoing percutaneous coronary intervention | Green Specialist Initiation |
| Prednisone MR | Rheumatoid arthritis (RA) | Black |
| Pre-exposure prophylaxis (PrEP) | For prevention of HIV in adults. Only as part of a clinical trial. Further details from NHS England | Black |
| Pretomanid | Multi-drug resitant TB | Red |
| Probiotics | Management of gastro-intestinal symptoms | Black (except VSL#3® which is 'green with specialist initiation' for ACBS criteria i.e. for the maintenance of remission of ileo-anal pouchitis). See NHSE Guidance on the conditions for which over the counter items should not routinely be prescribed in primary care. |
| Procarbazine | Treatment of cancers | Red |
| Protease inhibitors | HIV infection | Red |
| Protein C | As per BCSH guidelines for specialised indications | Red |
| Protein kinase inhibitors | Endocrinology; non-malignant conditions | Red |
| Prothrombin complex | As per BCSH guidelines for specialised indications | Red |
| Prucalopride | Chronic constipation in women when other laxatives fail to provide an adequate response - NICE TA211 | Green Specialist Initiation |
| Pyrazinamide | Treatment of TB | Red |
| Quetiapine | Atypical antipsychotic - schizophrenia | Green Specialist Initiation |
| Rabies vaccine | For travel use | Black NHSE items that should not be routinely prescribed in Primary Care |
| Radium-223 dichloride | Treatment of cancers | Red |
| Raltegravir | HIV infection | Red |
| Raltitrexed | Advanced colorectal cancer | Red |
| Ramucirumab | Treatment of cancers | Red |
| Ranibizumab | All indications | Red |
| Ranolazine | Only in accordance with NICE CG126 | Green Specialist Initiation |
| Rasagiline (Azilect®) | Parkinson's disease | Green Specialist Initiation |
| Rasburicase | Hyperuricaemia | Red |
| Regorafenib | Treatment of cancers | Red |
| Renavit® | Vitamin supplementation in renal impairment | Green Specialist Initiation |
| Reslizumab | Asthma | Red |
| Reveglucosidase alfa | Pompe disease | Red |
| Ribavirin | Chronic hepatitis C treatment | Red |
| Rifampicin | Treatment of TB | Red |
| Rifater® (rifampicin/isoniazid/pyrazinamide ) | Treatment of TB | Red |
| Rifaximin | Treatment of small intestinal bacterial overgrowth and for the treatment of chronic refractory pouchitis | Red |
| Rifaximin | Prevention of hepatic encephalopathy in adult patients | Green Specialist Initiation |
| Rifinah® (rifampicin/isoniazid) | Treatment of TB | Red |
| Rigosertib | Myelodysplastic syndromes (MDS); pancreatic cancer | Red |
| Rilonacept | Cryopyrin-associated periodic syndromes | Red |
| Rilpivirine | HIV infection | Red |
| Riluzole | To extend life or time to mechanical ventilation for patients with amyotrophic lateral sclerosis | Amber |
| Rimexolone ophthalmic suspension | Local ocular steroid anti-inflammatory | Green Specialist Initiation |
| Riociguat | Pulmonary arterial hypertension | Red |
| Risperidone injection (Risperdal Consta®) | Schizophrenia and other psychoses in patients tolerant to risperidone by mouth | Red |
| Risperidone oral | Atypical antipsychotic - schizophrenia | Green Specialist Initiation |
| Ritonavir | HIV infection | Red |
| Ritonavir/lopinavir | HIV infection | Red |
| Rituximab | All uses | Red |
| Rivaroxaban | See DOACs | See DOACs |
| Rivastigmine | Mild to moderate dementia in Alzheimer's disease | Green Specialist Initiation |
| Rivastigmine patches | Mild to moderate dementai in patients with swallowing difficulties | Green Specialist Initiation |
| Roflumilast (Daxas®) | As per TA461: Roflumilast, as an add-on to bronchodilator therapy, is recommended as an option for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis, only if: •the disease is severe, defined as a forced expiratory volume in 1 second (FEV1) after a bronchodilator of less than 50% of predicted normal, and •the person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid | Green Specialist Initiation |
| Romiplostim | Thrombocyclopenic purpura | Red |
| Ropeginterferon alfa-2b | Hepatitis C | Red |
| Ropinirole & ropinirole MR | Parkinson's disease | Green Specialist Initiation |
| Rotigotine transdermal patches | Parkinson's disease, either used alone or as an adjunct to levodopa with dopa-decarboxylase inhibitor | Green Specialist Initiation |
| Roxadustat | Dialysis-induced anaemia | Red |
| Rubefacients (excluding topical NSAIDs) | All indications | Black NHSE items that should not be routinely prescribed in Primary Care |
| Rufinamide | Adjunctive treatment of seizures in Lennox-Gastaut syndrome | Green Specialist Initiation |
| Ruxolitinib | Treatment of cancers | Red |
| Sacubitril valsartan | According to NICE TA388 for treating symptomatic chronic heart failure with reduced ejection fraction | Green Specialist Initiation |
| Safinamide | Parkinson's disease, as an adjunct to levodopa alone or in combination with other antiparkinsonian drugs, for mid- to late-stage fluctuations | Green Specialist Initiation |
| Sapropterin | Management of patients with phenylketonuria and tetrahydrobiopterin deficiency | Red |
| Saquinavir | HIV Infection | Red |
| Sarilumab | Paediatric indications (where adult NICE TAs are available) | Red |
| Sativex® Oromucosal Spray (cannabis-based product) | Spasticity and neuropathic pain in multiple sclerosis (MS) | Black. Also see information on the DROP-List |
| Saxagliptin | Type 2 diabetes (T2DM) | Green |
| Sebelipase alfa | Lysosomal acid lipase deficiency | Red |
| Secukinumab | All indications | Red |
| Selexipag | Pulmonary arterial hypertension | Red |
| Setrobuvir | Hepatitis C | Red |
| Sevelamer | Hyperphosphataemia in dialysis patients | Amber |
| Sevelamer | Adult renal dialysis | Red |
| Sialic acid | Myopathy | Red |
| Sildenafil | Post prostatectomy or radiotherapy | Green Specialist Initiation |
| Sildenafil | Off-label use for Raynaud's Disease. Pulmonary hypertension | Red |
| Silicone scar gels and sheets | When the specialist service recommending the treatment is funded by the NHS and has provided NHS funded care for that patient AND • The treatment is for hypertrophic or keloid scars that result from burns, trauma, keloid formation, or surgery and only when one or more of the following clinical criteria are met: a). Scar is functionally disabling b). Scar results in facial disfigurement | Green Specialist Initiation |
| Silk garments | Severe eczema and allergic skin conditions | Green Specialist Initiation |
| Simeprevir | Hepatitis C | Red |
| Sirolimus | Prophylaxis of organ rejection in transplant patients | Amber |
| Sirukumab | Paediatric indications (where adult NICE TAs are available) | Red |
| Sitagliptin | Type 2 diabetes (T2DM) | Green |
| Sodium aurothiomalate (IM gold) | Rheumatoid Arthritis | Amber |
| Sodium benzoate | Urea cycle disorders | Red |
| Sodium chloride 5% nebuliser solution | Unlicensed | Red |
| Sodium chloride 7% nebuliser solution (Nebusal®) | For patients with retained bronchopulmonary secretions and where usual treatment is not sufficiently effective | Green Specialist Initiation |
| Sodium clodronate (IV) | Bisphosphonate – osteolytic lesions, hypercalcaemia and bone pain associated with skeletal masses in breast cancer or multiple myeloma | Red |
| Sodium hyaluronate (Cystistat®) | Interstitial cystitis | Red |
| Sodium oxybate | Narcolepsy with cataplexy | Red |
| Sodium phenylbutyrate | Urea cycle disorders | Red |
| Sodium valproate Chronosphere® | Treatment of epilepsy | Green Specialist Initiation |
| Sofosbuvir | Hepatitis C | Red |
| Sofosbuvir/ledipasvir | Hepatitis C | Red |
| Sofosbuvir/velpatasvir | Hepatitis C | Red |
| Somatropin for adults | Acquired adult-onset post-surgery growth hormone deficiency *Please note that Omnitrope® is what we commission in adults as growth hormone product of choice* | Amber |
| Somatropin for paediatrics | For the treatment of Growth Hormone Insufficiency in Paediatrics | Green Specialist Initiation (see LTHT guidance) |
| Sorafenib | Treatment of cancers | Red |
| Stavudine | HIV infection | Red |
| Stiripentol | Rare forms of epilepsy | Red |
| Streptomycin | Treatment of TB | Red |
| Sucraid® | Treatment of sucrase-isomaltase deficiency | Red |
| Sucroferric oxyhydroxide | Control of serum phosphorus levels in dialysis patients | Red |
| Sugammadex | Reversal of neuromuscular blockade induced by rocuronium or vecuronium | Red |
| Sucralfate | All indications | Red |
| Sulfasalazine | Licensed indication - rheumatoid arthritis (RA). Off-label - other inflammatory arthritides | Amber |
| Sunitinib | Treatment of cancers | Red |
| Susoctocog alfa | Haemophilia A | Red |
| Tabalumab | Systemic lupus erythematosus (SLE) | Red |
| Tacrolimus (oral) | Immunosuppressant for transplant patients | Amber |
| Tacrolimus | Post paediatric renal transplant | Amber |
| Tacrolimus (Adaport®) | Treatment of Crohns Disease unresponsive to other immunosuppressants (off-label use) | Amber |
| Tacrolimus | Nephrotic Syndrome in children | Amber |
| Tacrolimus (topical) | Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids | Green |
| Tadalafil | Penile rehabilitation post radical prostatectomy or radiotherapy | Black |
| Tadalafil once daily | Erectile dysfunction | Black NHSE items that should not be routinely prescribed in Primary Care |
| Tadalafil | Pulmonary arterial hypertension | Red |
| Tafluprost | Glaucoma | Green Specialist Initiation |
| Taliglucerase alfa | Gaucher's disease | Red |
| Talimogene laherparepvec | Treatment of cancers | Red |
| Taribavirin | Hepatitis C | Red |
| Tapentadol modified-release tablets | Chronic non-malignant pain | Green Specialist Initiation |
| Taurine | Cystic fibrosis (CF) management | Amber - SCG not available. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. |
| TB drugs | Red when used for TB | Red |
| Teduglutide | Short bowel syndrome | Red |
| Tegafur with uracil | Treatment of cancers | Red |
| Telaprevir | Hepatitis C | Red |
| Telbivudine | Hepatitis B | Red |
| Temozolomide | Treatment of cancers; endocrinology; non-malignant conditions | Red |
| Temsirolimus | Treatment of cancers | Red |
| Tenofovir alafenamide fumarate | Hepatitis B | Red |
| Tenofovir disoproxil fumarate | HIV infection | Red |
| Tenofovir/cobicistat/elvitegravir/emtricitabine | HIV infection | Red |
| Tenofovir/efavirenz/emtricitabine | HIV infection | Red |
| Tenofovir disoproxil fumarate/emtricitabine | HIV infection | Red |
| Tenofovir/emtricitabine/elvitegravir/cobicistat | HIV infection | Red |
| Tenofovor/emtricitabine/rilpiverine | HIV infection | Red |
| Teriflunomide | Multiple sclerosis (MS) | Red |
| Teriparatide | All indications | Red |
| Testosterone gels | Hypogonadism due to testosterone deficiency inn men | Green Specialist Initiation |
| Testosterone injections (all brands) | Use in line with licensed indications | Green Specialist Initiation |
| Tetrahydrobiopterin | Phenylketonuria | Red |
| Thalidomide | All indications | Red |
| Thrombin | Pseudoaneurysm | Red |
| Ticagrelor | Antiplatelet drug - use in line with NICE TA236 and TA420 | Green Specialist Initiation |
| Tick-bourne encephalitis vaccine | For travel use | Black NHSE items not to be routinely prescribed in Primary Care |
| Timolol/brinzolamide eye erops (Azarga®) | Glaucoma | Green Specialist Initiation |
| Tioguanine | Treatment of cancers | Red |
| Tipranavir | HIV infection | Red |
| Tizanidine | Spasticity | Green Specialist Initiation |
| Tobramycin | Red for newly diagnosed CF Patients | Red |
| Tobramycin (Tobi®) nebuliser solution | Cystic fibrosis (CF) management | Amber |
| Tobramycin dry powder inhaler | Suppression of chronic pulmonary infections in cystic fibrosis | Red |
| Tocilizumab | All indications | Red |
| Tofacitinib | Paediatric indications (where adult NICE TA available) | Red |
| Tofacitinib | XELJANZ® in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have inadequately responded to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs). XELJANZ® can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate. | Red |
| Tolvaptan | Hyponatraemia secondary to secretion of inappropriate antidiuretic hormone secretion (SIADH) | Red |
| Topotecan | Cancer chemotherapy | Red |
| Toremifine | Metastatic breast cancer | Green Specialist Initiation |
| Total parenteral nutrition (TPN) | Intravenous nutrition - various indications | Red |
| Trabectedin | Treatment of cancers | Red |
| TraLife® oral spray | Oral hygeine | Red |
| Tralokinumab | Asthma | Red |
| Trametinib | Treatment of cancers | Red |
| Trastuzumab | Treatment of cancers | Red |
| Trastuzumab emtansine | Treatment of cancers | Red |
| Travoprost/timolol (Duotrav®) | Rasied intra-ocular pressure | Green Specialist Initiation |
| Trenonacog alpha | Haemophilia B | Red |
| Treosulfan | Treatment of cancers | Red |
| Treprostinil | Pulmonary arterial hypertension | Red |
| Tretinoin (oral) | Antineoplastic; induction of remission in acute promyelocytic leukaemia | Red |
| Triamcinolone hexacetonide (Lederspan®) | Unlicensed - depot steroid injection for use in children | Red |
| Trientine | Wilson's disease | Red |
| Trifluridine/tipiracil | Treatment of cancers | Red |
| Trimipramine vaccine | For travel use | Black NHSE items not to be routinely prescribed in Primary Care |
| Triptorelin | Endometriosis or uterine fibroids | Amber - see GnRH analogues |
| Triptorelin | IVF treatment; male hypersexuality | Red |
| Triptorelin | Precocious puberty | Amber - SCG not available. Please see Amber classification definition for further information and seek advice from requesting consultant for monitoring requirements. |
| Triptorelin | Management of prostate cancer | Amber - see GnRH analogues |
| Trospium MR | Urinary incontinence | Green |
| Trospium XL | Urinary incontinence | Green |
| Tryptophan | Severe disabling depression. Unlicensed product - named patient use only | Red |
| Turotocog alfa | As per BCSH guidelines | Red |
| Ulipristal (Esmya®) | 1. Pre-operative management of uterine fibroids. Alternative treatment to hysterectomy, myomectomy, uterine embolization or GnRH agonists in perimenopausal patients with moderate to severe symptoms caused by fibroids. Also considered in younger patients with high surgical/anaesthetic risks. 2. Intermittent treatment of moderate to severe symptoms of uterine fibroids | Red |
| Ultibro Breezhaler® | Chronic obstructive pulmonary disease (COPD) | Green |
| Urofollitrophin | IVF treatment | Red |
| Ustekinumab | All indications | Red |
| Vadadustat | Dialysis-induced anaemia | Red |
| Valganciclovir | All indications | Red |
| Valproate | All indications | Green Specialist Initiation |
| Vandetanib | Thyroid cancer | Red |
| Vardenafil | Penile rehabilitation post radical prostatectomy or radiotherapy | Black |
| Vedolizumab | All indications | Red |
| Velaglucerase alfa | Gaucher's disease | Red |
| Velcalcetide | Hyperparathyrodism | Red |
| Vemurafenib | Melanoma | Red |
| Venlafaxine (at doses over 300mg daily) | Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of social anxiety disorder. Treatment of panic disorder, with or without agoraphobia | Green |
| Verteporfin | Age related macular degeneration | Red |
| Viekirax® | Hepatitis C | Red |
| Vildagliptin | Type 2 diabetes (T2DM) | Green |
| Vildagliptin with metformin | Type 2 diabetes (T2DM) | Green |
| Vinblastine | Treatment of cancers | Red |
| Vincristine | Treatment of cancers | Red |
| Vindesine | Treatment of cancers | Red |
| Vinorelbine | Treatment of cancers | Red |
| Vismodegib | Treatment of cancers | Red |
| Vitamin A | Retinosa pigmentosa | Red |
| Viteyes 2® | Advanced age-related macular degeneration (AMD) in patients with category 4 disease. See commissioning statement | Green Specialist Initiation |
| Voluvyte® injection | Plasma expander | Red |
| Von Willebrand factor, recombinant | Von Willebrand deficiency | Red |
| Voriconazole | Anti-fungal agent | Red |
| Vortioxetine | For treating major depressive episodes | Green Specialist Initiation |
| VSL#3® | Management of GI symptoms | Green Specialist Initiation (IF prescribed as per criteria specified in the commissioning statement. See statement on the relevant CCG website) |
| Yellow fever vaccine | For travel use | Black Items that should not be routinely prescribed in Primary Care |
| Ziconotide | Non-opioid analgesic administered by intrathecal infusion | Red |
| Zidovudine | HIV infection | Red |
| Zoledronic acid | Prevention of skeletal related events (pathological, spinal compression, radiation/surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone; treatment of tomour-induced hypercalcaemia | Red |
| Zuclopenthixol depot injection | Depot antipsychotic for schizophrenia | Green Specialist Initiation |